Asenapine transdermal delivery system (Secuado®) in schizophrenia: a profile of its use in the USA
online resourceposted on 20.04.2021, 06:57 by Young-A Heo
Funding The preparation of this review was not supported by any external funding.
Authorship and conflicts of interest Y.-A. Heo is a salaried employee of Adis International Ltd/Springer Nature, is an editor of Drugs & Therapy Perspectives, was not involved in any publishing decision for the manuscript, and declares no relevant conflicts of interest.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug Q&A can be found here
Asenapine, an atypical antipsychotic indicated for the treatment of schizophrenia, was first available as a twice-daily sublingual tablet. However, there are some challenges associated with the use of sublingual asenapine. More recently, a comparable transdermal formulation of asenapine (Secuado®) has been approved in the USA as the first antipsychotic patch for the treatment of schizophrenia in adults. Asenapine transdermal delivery system (TDS) offers a simpler and more convenient dosage regimen and avoids adverse events related to sublingual administration, potentially leading to better adherence to treatment. In a pivotal 6-week phase 3 study in patients with an acute exacerbation of schizophrenia, once-daily application of asenapine TDS 3.8 mg/24 h and 7.6 mg/24 h significantly reduced psychotic symptoms and global disease severity compared with placebo. Asenapine TDS is generally well tolerated, with the systemic safety profile being largely consistent with that established for sublingual asenapine. Although the use of asenapine TDS is associated with application site reactions, these reactions are generally mild to moderate in severity.
Springer Nature Switzerland AG 2021